Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.57 |
| ▸ | FOLH1 | Q04609 | 7/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.42 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.41 |
| ▸ | EPOR | P19235 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11920365 | 1.00 | GLP1R (0.57) | GLP1RFOLH1EPHX2NOD1EPOR | |
| SCHEMBL11920369 | 1.00 | GLP1R (0.57) | GLP1RFOLH1EPHX2NOD1EPOR | |
| SCHEMBL14118023 | 1.00 | GLP1R (0.57) | GLP1RFOLH1EPHX2NOD1EPOR | |
| SCHEMBL13146856 | 0.96 | GLP1R (0.58) | GLP1RFOLH1EPHX2NOD1EPOR | |
| SCHEMBL13146866 | 0.96 | GLP1R (0.58) | GLP1RFOLH1EPHX2NOD1EPOR | |
| SCHEMBL13146869 | 0.96 | GLP1R (0.58) | GLP1RFOLH1EPHX2NOD1EPOR | |
| SCHEMBL13146823 | 0.94 | GLP1R (0.67) | GLP1RFOLH1NOD1 | |
| SCHEMBL14117968 | 0.94 | GLP1R (0.67) | GLP1RFOLH1NOD1 | |
| SCHEMBL14117977 | 0.94 | GLP1R (0.67) | GLP1RFOLH1NOD1 | |
| SCHEMBL14117971 | 0.94 | GLP1R (0.67) | GLP1RFOLH1NOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859493-B2 | Insulin derivatives | NOVO NORDISK A/S (DK) | 2014-10-14 | — | — | US | disclosed |
| US-20120208749-A1 | Insulin derivatives | NOVO NORDISK A/S (DK) | 2012-08-16 | — | — | US | disclosed |
| US-20100227796-A1 | Insulin Derivatives | NOVO NORDISK A/S (DK) | 2010-09-09 | — | — | US | disclosed |
| US-20080171695-A1 | Acylated with polyethylene glycol, polypropylene glycol or polybutylene glycol in combination with a fatty diacid; improved bioavailability, first pass effect, solubility at physiological pH values and prolonged pharmacokinetics | NOVO NORDISK A/S (DK) | 2008-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227796-A1 | Insulin Derivatives | IAPP, INSR, GCG | GLP1R 19/4885FOLH1 1378/4885EPHX2 1255/4885 |
| US-20120208749-A1 | Insulin derivatives | IAPP, INSR, GCG | GLP1R 22/4885FOLH1 1262/4885EPHX2 1446/4885 |
| US-20080171695-A1 | Acylated with polyethylene glycol, polypropylene glycol or polybutylene glycol in combination with a fatty diacid; improved bioavailability, first pass effect, solubility at physiological pH values and prolonged pharmacokinetics | IAPP, FABP4, INSR | GLP1R 134/4885FOLH1 2002/4885EPHX2 2749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.